Business Context and Reporting Period
Company: Context Therapeutics Inc. (CNTX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2025
Reporting Period: Single event date (January 14, 2025)
Business Context: The Company is an emerging growth company focused on clinical development. This filing reports a significant milestone in its Phase 1 clinical trial for the investigational therapy CTIM-76.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the initiation of patient dosing in the Phase 1 clinical trial for CTIM-76. This represents a progression in the Company's clinical development pipeline compared to the prior period where this specific trial had not yet begun dosing.
Guidance, Outlook, and Management Commentary
- Clinical Milestone: The first patient was dosed in the Phase 1 clinical trial evaluating CTIM-76 on January 14, 2025.
- Data Outlook: Management anticipates sharing initial data from the CTIM-76 Phase 1 trial in the first half of 2026.
- Regulatory Disclosure: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial design and safety parameters.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor future announcements for the anticipated initial data release in the first half of 2026.
- Review the Company's status as an emerging growth company for potential differences in financial reporting requirements.